Register to chat with like-minded investors on our interactive forums.
Period:
Draw Mode:
| Volume | 0 |
|
|||||
| News | - | ||||||
| Day High | Low High |
||||||
| Day Low | |||||||
| Company Name | Stock Ticker Symbol | Market | Type |
|---|---|---|---|
| Tarsus Pharmaceuticals Inc | TARS | NASDAQ | Common Stock |
| Price Change | Change Percent | Stock Price | Last Traded
|
|
|---|---|---|---|---|
| 0.00 | 0.00% | 33.71 | 08:48:13 |
| Open Price | Low Price | High Price | Close Price | Prev Close |
|---|---|---|---|---|
| 33.71 |
| Trades | Volume | Avg Volume | 52 Week Range |
|---|---|---|---|
| 0 | 0 | - | 12.57 - 40.40 |
| Last Trade Time | Type | Quantity | Stock Price | Currency |
|---|---|---|---|---|
| - | 0 | $ 33.71 | USD |
Tarsus Pharmaceuticals Inc Financials
| Market Cap | Shares in Issue | Float | Revenue | Profit/Loss | EPS | PE Ratio |
|---|---|---|---|---|---|---|
| 1.15B | 34.22M | - | 17.45M | -135.89M | -3.97 | - |
| Short Interest | Dividends Per Share | Dividend Yield | Ex-Div Date | Insider B/S | Insider % Owned |
|---|---|---|---|---|---|
| - | - | - | - |
Tarsus Pharmaceuticals News
Loading Messages....
|
|
{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}} |
Loading Messages....
Historical TARS Price Data
| Period | Open | High | Low | VWAP | Avg. Daily Vol | Change | % |
|---|---|---|---|---|---|---|---|
| 1 Week | 35.11 | 35.11 | 31.72 | 33.00 | 364,012 | -1.40 | -3.99% |
| 1 Month | 33.60 | 38.46 | 31.72 | 35.37 | 565,536 | 0.11 | 0.33% |
| 3 Months | 27.46 | 40.40 | 27.10 | 33.67 | 725,403 | 6.25 | 22.76% |
| 6 Months | 13.22 | 40.40 | 12.87 | 26.40 | 695,250 | 20.49 | 154.99% |
| 1 Year | 14.73 | 40.40 | 12.57 | 23.21 | 532,459 | 18.98 | 128.85% |
| 3 Years | 30.52 | 40.40 | 10.8001 | 21.72 | 236,162 | 3.19 | 10.45% |
| 5 Years | 18.30 | 63.69 | 10.8001 | 22.41 | 211,827 | 15.41 | 84.21% |
Tarsus Pharmaceuticals Description
| Tarsus Pharmaceuticals Inc is a late clinical-stage biopharmaceutical company. It is focused on the development and commercialization of first-in-class therapeutic candidates to provide treatment for ophthalmic conditions. The company's lead candidate TP-03, is a novel drug that targets the Demodex mite nervous system to kill the mites. |
